https://www.selleckchem.com/pr....oducts/NVP-AUY922.ht
Prospective, randomized, phase 3 trials comparing the 2 strategies, conducted within homogenous disease settings, with consistently evaluated functional and imaging endpoints, are not available to guide the risks/benefit discussion. As is often the case in rare biologically diverse diseases, in a vulnerable population, therapy decisions are frequently based on incomplete data, physician experience, bias to some degree, and patient/family preference. © The Author(s) 2019. Published by Oxford University Press on behalf of the Society f
Gefällt mir
Kommentar
Teilen
